Twitter Beğeni Hilesi

Our latest meta-analysis on #chemoradiation in nasopharyngeal cancer out in The Lancet Oncology Huge collaborative work. ✅ 28 trials, 8.000+ pts, 7.6y FU ✅ more chemo (ind+conc or conc+adj) ➡️superior (OS/PFS) to CRT alone but more tox Free 50day link: authors.elsevier.com/a/1hAd45EIIgLp…

The European Society for Radiotherapy and Oncology (ESTRO) issued the following statement regarding the PROSPECT clinical trial for patients with resectable rectal cancer: lnkd.in/eAKgFCru #radiotherapy #radiationoncology #radonc

📝Preprint Alert📝 Check out our real-world study: 1st-line #pembrolizumab for #headandneck SCC: tinyurl.com/3rmhy9kk A collaboration between 5 tertiary cancer centres that serve all 5.3 mil people in Scotland #medtwitter #oncology #medstudenttwitter Highlights below 1/2

Highlights: 🔹Comparable outcomes to KEYNOTE-048 trial 🔸Immune-related AEs associated with better outcomes for pembrolizumab Rx 🔹Locally advanced, treatment naïve patients (>1/3 of our cohort, lower representation in KEYNOTE-048) had comparable outcomes to others 2/2

About to leave Aberdeen for Birmingham to join the head and neck cancer session at Oncology Forum UK to discuss the management of recurrent tumours #headandneckcancer #radiotherapy #OF23

Nice to see colleagues face to face after a long time Oncology Forum UK. Excellent discussion about treatment of recurrent head and neck cancer and integration of therapeutic modalities. Now it's time to go back to Aberdeen. #OF23 #headandneckcancer NHS Grampian Integrated Specialist Care Services Portfolio

Another patient enrolled in PETNECK 2 trial NHS Grampian. Patient initiated follow up is a novel and exciting approach to post-treatment care in H&N cancer #headandneckcancer #realisticmedicine Research Awareness Grampian Integrated Specialist Care Services Portfolio Hisham Mehanna Paul Nankivell

On #WorldHeadAndNeckCancerDay we are highlighting a new study for Head & Neck Cancer patients in Aberdeen. It's looking at a new medicine given as a mouthwash before radiotherapy. It's hoped that it will prevent severe oral mucositis. grampianclinicalresearch.com/news Rafael Moleron

One day after #WorldHeadAndNeckCancerDay NHS Grampian we have enrolled our 50th patient in CompARE and our 2nd patient in NG11-2-P1b trial. We continue working to find better treatments for H&N cancer in partnership with our patients. Research Awareness Grampian Hisham Mehanna InHANSE RESEARCH

Innovation in cancer NHS Grampian Integrated Specialist Care Services Portfolio thetimes.co.uk/article/c20384…

And we have the 100th patient randomised! Congratulations to East Kent Hospital East Kent NHSFT R&I....a milestone achieved for which we would like to thank all our recruiting NHS sites. Birmingham Cancer Research UK Clinical Trials Unit Paul Nankivell Hisham Mehanna InHANSE RESEARCH

Tackling cancer with teamwork! Great to present our research, a collaboration across the entire Scottish Cancer Network, at a network meeting. #MedTwitter #oncology South East Scotland Cancer Network (SCAN) Office of the Chief Executive NHSScotland

#ESTRO2024 alerts: 1. Accommodation is booking up quickly - reserve now: estro.org/Congresses/EST… 2. It might be easier to fly to Edinburgh Airport and take the bus to Glasgow - 1 hour trip, every 30 minutes. edinburghairport.com/transport-link… ESTRO Glasgow Convention Bureau #radonc #radbio

📗 The abstract book for #ESTRO24 is now online! Access the latest #research in #RadiationOncology to be presented at the congress: 👉bit.ly/49y1iJm #radonc #radiotherapy #innovations

Ready for #ESTRO24, with great representation of our Aberdeen NHS Grampian team with contributions in #adaptiveradiotherapy #headandneckcancer Research Awareness Grampian Integrated Specialist Care Services Portfolio

What is LC w/ high dose RT chordoma/chondrosarcoma? · Phase I/II · Chordoma 72-79.2Gy · Chondro 70.2-73.8Gy · doi.org/10.1016/j.adro…

Heading back to Aberdeen after sharing our experience in the implementation of #adaptiveradiotherapy with ETHOS UKIOCongress. Great session with a very inquisitive audience. @varianuk Varian. Tomorrow back to work NHS Grampian Integrated Specialist Care Services Portfolio

5-y results of JCOG 1008 study comparing weekly vs three-weekly cisplatin as concomitant chemoRT for postop head neck cancer. At 5y, weekly non inferior for ✅OS ✅PFS ✅locoregional control Similar toxicity Dr Tahara at #ESMO2024

Congrats to my friend Yungan TAO & GORTEC for this huge trial of IO in LA HNSCC Avelumab-cetuximab inferior to cisplatin CRT in fit patients but superior to cetuximab-RT for PFS in cisplatin ineligible population. #ESMO2024

LOVE this study. No ENI (GTV only) and only 2 (out of 56) nodal failures. Many caveats (F/U, competing non-cancer risks, in-field failures, etc). However, let's not give durva too much credit here, though it may have helped. It is possible that ENI is overrated...